Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BOLD
stocks logo

BOLD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.520
-29.73%
--
--
-0.575
-19.01%
--
--
-0.595
-15%
Estimates Revision
Stock Price
Go Down
down Image
-4.35%
In Past 3 Month
Wall Street analysts forecast BOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLD is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLD is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.100
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 1.100
sliders
Low
4.00
Averages
4.00
High
4.00
H.C. Wainwright
Buy
downgrade
$5 -> $4
2025-08-11
Reason
H.C. Wainwright
Price Target
$5 -> $4
2025-08-11
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Boundless Bio to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.
Goldman Sachs
Richard Law
initiated
2025-07-24
Reason
Goldman Sachs
Richard Law
Price Target
2025-07-24
initiated
Reason
Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio with an Early-Stage Biotech rating, saying the company's combo approach for its lead asset BBI-355 comes with high risk.
H.C. Wainwright
NULL -> Buy
initiated
$5
2025-06-02
Reason
H.C. Wainwright
Price Target
$5
2025-06-02
initiated
NULL -> Buy
Reason
Leerink
Outperform -> Market Perform
downgrade
$15 -> $3
2025-05-27
Reason
Leerink
Price Target
$15 -> $3
2025-05-27
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Boundless Bio to Market Perform from Outperform with a price target of $3, down from $15. The company is discontinuing current monotherapy and combination arms of BBI-355 in the Phase 1/2 POTENTIATE clinical trial based on a narrow therapeutic index observed with dosing, the analyst tells investors in a research note. The firm is moving to the sidelines pending validation of Boundless Bio's new approach. It removed all value for the CHK1 program until the company validates the BBI-355 and BBI-825 combination hypothesis in specific tumor types.
Guggenheim
Yige Guo
Strong Buy
to
Hold
Downgrades
n/a
2024-12-13
Reason
Guggenheim
Yige Guo
Price Target
n/a
2024-12-13
Downgrades
Strong Buy
to
Hold
Reason
Guggenheim analyst Michael Schmidt downgraded Boundless Bio to Neutral from Buy.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Boundless Bio Inc (BOLD.O) is -0.48, compared to its 5-year average forward P/E of -1.01. For a more detailed relative valuation and DCF analysis to assess Boundless Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.01
Current PE
-0.48
Overvalued PE
-0.15
Undervalued PE
-1.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.15
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.06
Undervalued EV/EBITDA
-2.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BOLD News & Events

Events Timeline

(ET)
2025-11-05
07:02:41
Boundless Bio anticipates funding to last until the first half of 2028.
select
2025-11-05
07:02:07
Boundless Bio Announces Q3 Earnings Per Share of 62 Cents, Exceeding Consensus Estimate of 58 Cents
select
2025-08-05 (ET)
2025-08-05
07:05:25
Boundless Bio reports Q2 EPS (70c), consensus (65c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
08-05Newsfilter
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

  • POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.

  • Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.

[object Object]
Preview
5.0
07-31Newsfilter
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

  • Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.

  • Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.

[object Object]
Preview
1.0
06-06Newsfilter
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

  • Company Announcement: Boundless Bio, a clinical-stage oncology company, will have its CEO Zachary Hornby participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami, FL.

  • Research Focus: The company is dedicated to developing therapies targeting extrachromosomal DNA (ecDNA) in oncogene amplified cancers, with ongoing clinical trials for their therapeutic candidates BBI-355 and BBI-825.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Boundless Bio Inc (BOLD) stock price today?

The current price of BOLD is 1.1 USD — it has increased 1.85 % in the last trading day.

arrow icon

What is Boundless Bio Inc (BOLD)'s business?

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

arrow icon

What is the price predicton of BOLD Stock?

Wall Street analysts forecast BOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLD is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Boundless Bio Inc (BOLD)'s revenue for the last quarter?

Boundless Bio Inc revenue for the last quarter amounts to -15.15M USD, decreased -19.06 % YoY.

arrow icon

What is Boundless Bio Inc (BOLD)'s earnings per share (EPS) for the last quarter?

Boundless Bio Inc. EPS for the last quarter amounts to -10210000.00 USD, decreased -25.74 % YoY.

arrow icon

What changes have occurred in the market's expectations for Boundless Bio Inc (BOLD)'s fundamentals?

The market is revising No Change the revenue expectations for BOLD for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -4.35%.
arrow icon

How many employees does Boundless Bio Inc (BOLD). have?

Boundless Bio Inc (BOLD) has 64 emplpoyees as of December 05 2025.

arrow icon

What is Boundless Bio Inc (BOLD) market cap?

Today BOLD has the market capitalization of 24.62M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free